Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27

Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.